Reslizumab intravenous (IV) vs placebo
Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma
Reslizumab intravenous (IV) leads to lower rate of clinically significant exacerbations requiring systemic… compared with placebo (high certainty).
1 finding from 1 review
- Rate ratio 0.43 [0.33, 0.55]2 studies · 953 participantsHigh